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ABSTRACT 
Hot melt extrusion (HME) was evaluated as a continuous processing technology for the 
manufacture of solid dispersions. The aim of the current research project was to study the effect 
of pressurized carbon dioxide (P-CO2) on the physico-mechanical properties of three different 
grades of cellulose polymers, Klucel™ ELF, EF and LF hydroxypropylcellulose (HPC) resulting 
from hot melt extrusion techniques, and to assess the plasticization effect of P-CO2 on the tested 
polymers. The physico-mechanical properties as well as the tablet characteristics of the 
extrudates with and without injection of P-CO2 and with non-extruded polymers were examined. 
P-CO2 acted as plasticizer for Klucel™ LF, EF and ELF and allowed for a reduction in 
processing temperature during the extrusion process by 20°C as compared to the processing 
temperature without injecting P-CO2. Furthermore, the CO2 served as a pore former and 
produced foam-like structure extrudates. This morphological change resulted in an increase in 
bulk and tap density as well as surface area and porosity. Additionally, the hardness of the tablets 
of the polymers with P-CO2 was increased compared to polymer processed without P-CO2 and 
the non-extruded polymer. Moreover, the % friability of the tablets improved using P-CO2 
processed polymer. Thus good binding properties and compressibility of the extrudates were 
positively influenced utilizing P-CO2 processing.   
The interest to incorporate a model was increased to investigate the effect of pressurized 
carbon dioxide (P-CO2) on the physico-mechanical properties as well as the drug release 
behavior.   
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Ketoprofen (KTP), used as a model drug, was incorporated with hydroxypropylcellulose 
(HPC) (Klucel™ ELF, EF and LF) as a polymeric carrier to produce KTP amorphous solid 
dispersion using HME technique.  Thermal gravimetric analysis (TGA) was used to evaluate and 
confirm the formulations thermal stability. Differential Scanning Calorimetery (DSC) was 
performed to evaluate the physical state of KTP in the extrudates. The microscopic morphology 
of the extrudates was changed to a foam-like structure due to expansion of the CO2 at the 
extrusion die. The foamy extrudates demonstrated enhanced KTP release compared to the 
extrudates processed without P-CO2 due to the increase in porosity and surface area of those 
extrudates. The moisture content of the extrudates processed with P-CO2 was slightly increased 
and this played a significant role in increasing KTP tablet hardness and decreasing percent 
friability.  
A concern with HME is the limitation of the drug loading due to drug-polymer 
miscibility. In order to solve this issue, we investigated the effect of foam like structure produced 
by pre P-CO2 on the drug loading and the dissolution profile of carbamazepine (CBZ) and low 
molecular weight hydroxypropylcellulose (HPC) matrices using HME technique. The resulted 
extrudates with P-CO2 injection exhibited higher surface area and porosity compared to the 
extrudates processed without P-CO2. Moreover, the CBZ release profile of the 20-50% drug load 
formulations processed with P-CO2 injection showed almost complete drug release within 2 
hours. In contrast, the drug release profiles of 20%, 30%, 40% and 50% CBZ/ Klucel™ ELF 
formulations processed without P-CO2 injection exhibited 90%, 86%, 80% and 73% CBZ drug 
release, respectively. In conclusion, HME processing assisted with P-CO2 increased the drug 
loading capability of CBZ in KlucelTM ELF polymeric matrix as well as optimized CBZ drug- 
release profiles. 
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Drug permeability and dissolution rate are considered as key to predict the drug 
bioavailability. HME was used as an approach to improve solubility and permeability of the 
psychoactive natural product piperine. Piperine 10–40% w/w formulated in Eudragit® EPO/ 
Kollidon® VA 64 or Soluplus® formulation was used in this study to investigate the efficiency of 
various polymers to enhance the solubility and permeability of piperine via HME technique to 
ultimately increase its systemic absorption of the compound.  Scanning electron microscopy 
(SEM) images showed absence of crystals in 10% w/w piperine/Soluplus® indicating that 
piperine was dispersed in the Soluplus® polymer carrier in its amorphous form. However, 
crystals were evident in all other formulations with different ratios. Solubility of 10% and 20% 
piperine/Soluplus® was increased more than 160 and 45 folds in water, respectively. 
Furthermore, permeability studies using non- everted rat intestinal sac model demonstrated the 
enhancement in piperine absorption of the 10% w/w piperine/Soluplus® extrudates up to 158.9 
μg/5mL compared to 1.4 μg/5mL in the case of pure piperine within 20 minutes. 
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CHAPTER I 
INTRODUCTION 
Hot melt extrusion (HME) is a well-known processing technology which represents a novel 
method to prepare solid dispersions. HME can simply be defined as a mixture of one or more 
active pharmaceutical ingredients and at least one polymeric carrier forced through extrusion die 
under controlled conditions to form a solid solution [1]. Being fast, simple, continuous and a 
solvent free process, HME has received great attention in the pharmaceutical industry [2].  
On the other hand most of the polymeric carriers have a high glass transition temperature (Tg) of 
150 oC or more. Therefore, incorporation of a plasticizer is required in order to facilitate the 
processing conditions as well as enhance the stability of the extrudates. The use of plasticizers 
will lower the polymer viscosity due to the reduction in polymer Tg and therefore, increases the 
thermal stability and minimizes the material thermal decomposition. There are many factors to 
be considered to choose the suitable plasticizer such as the plasticizer efficiency, the plasticizer-
polymer compatibility and the plasticizer stability. The resulting extrudates exhibit an elastic 
smooth surface and low porosity. These extrudates properties may lower the formulation drug 
release and also decrease the milling efficiency of those extrudates. The percentage of the 
plasticizers in the formulation varies depending on the type of polymeric carrier as well as the 
plasticizer efficacy.  Incorporating plasticizers in pharmaceutical formulations will increase the 
formulations final weight and result in patients complaints. Therefore, the use of a physical 
2 
 
blowing agent as a reversible plasticizer has gained a great interest in HME processing 
technology. 
Carbon dioxide (CO2) is considered as a great example for a physical blowing agent. It acts as a 
reversible plasticizer and foaming agent [3]. CO2 is chemically inert and present in four different 
state, with the change from state to state mainly depends on its temperature and the pressure. 
Figure 1-1 shows the phase diagram of CO2 and its critical point of 31
oC and 1073 Psi.  
 
 
 
 
 
 
 
 
 
 
Figure 1-1: Phase diagram of carbon dioxide (CO2) [4] 
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There are many pharmaceutical applications for supercritical CO2 (SC-CO2) such as a 
replacement to organic solvents in extraction, micro and nano particales formation, co-solvents, 
co-precipitating agent, co-crystalizing agent, and in co-precipitation and solid dispersion 
formation [5]. Additionally, there are also future prospects for the use of CO2  as a sterilizing 
agent [6].  
As hot melt extrudates have very low porosity structure which may slow down the penetration of 
dissolution medium and alter the drug release, P-CO2 could be used as a blowing agent to 
provide foamy extrudates with solid porous structure, therefore enhance the drug release. 
Generally, production of foamed extrudates includes three main steps with in the drug polymer 
mixtures; cell nucleation, cell growth and finally, the stabilization step [7].  At the first step, the 
blowing gas implemented the melted mixture then the cell nucleation of the foam is initiated. At 
the second step, expansion of the gas takes place, in which the growth of the foam structure 
occurs. On the stabilization step, the foam formation is completed and the excess gas escapes at 
the extrusion die.  
Formation of foamy hot melt extrudates is described schematically in Figure 1-2. At the P-CO2 
injection site, the sudden reduction in pressure and the increase in the temperature allows for the 
diffusion of CO2 into the melted material. This condition helps to start the foam nucleation and 
the foam structure growth [8].  
 
 
 
4 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
-2
: 
S
ch
e
m
a
ti
c 
d
ia
g
ra
m
 f
o
r 
th
e 
fo
r
m
a
ti
o
n
 o
f 
fo
a
m
y
 e
x
tr
u
d
a
te
s 
v
ia
 h
o
t 
m
el
t 
ex
tr
u
si
o
n
 
p
ro
ce
ss
. 
5 
 
Biopharmaceutics classification system divides the drug into four classes (figure 1-3) depending 
on two important factors, solubility and permeability. These factors play a big role in the drug 
absorption and bioavailability.  Class I drug having no bioavailability issues as they have good 
solubility and permeability and hence are easy to formulate for oral administration. While class 
IV is considered the most difficult one as it represents the drug category which has poor 
solubility and poor permeability. On the other hand, the biopharmaceutical properties of class II 
(poor solubility/good permeability) and class III (good solubility and poor permeability) can be 
modified to develop enhanced bioavailability oral formulations. These modifications can be 
through enhancing the solubility via HME and other techniques or enhancing the permeability of 
those drugs. Depending on the drug permeability mechanism of action, different methods can be 
used to enhance the permeability. Permeability enhancers can be used in case of active 
transportation mechanism while the HME can be used in case of passive transportation 
mechanism.   
 
 
 
 
 
 
 
Figure 1-3: Biopharmaceutics classification system by Shugarts et al. [9] 
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The specific objectives to the current research projects were to study the effect of P-CO2 on the 
drug release and drug loading capacity using Ketoprofen (KTP) and Carbamazepine as drug 
models. In addition, investigate the effect of different polymeric carriers using HME on the 
solubility and permeability of a model drug piperine, is investigated.  
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CHAPTER II 
RESEARCH PROJECTS AND OBJECTIVES 
2.1. Effect of Pressurized Carbon Dioxide on the Physico-Mechanical Properties of Hot 
Melt Extruded Cellulose Polymers 
2.1.1. Objectives: 
The aims of the this research project were 
1. To study the effect of Pressurized carbon dioxide (P-CO2) on the physico-mechanical 
properties of cellulose polymers, Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC) 
resulting from hot melt extrusion techniques. 
2.  To assess the plasticization effect of P-CO2 on the polymers tested (Klucel™ LF, EF and 
ELF hydroxypropylcellulose (HPC). 
2.2. Influence of Pressurized Carbon Dioxide on Ketoprofen-Incorporated Hot-Melt 
Extruded Low Molecular Weight Hydroxypropylcellulose 
2.2.1. Objective: 
The goals of the current research project were to: 
1. Investigate the effect of pressurized carbon dioxide (P-CO2) on the physicomechanical 
properties of Ketoprofen (KTP) and hydroxypropylcellulose (HPC) matrices produced using 
hot-melt extrusion (HME) techniques. 
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2. Study the tablet characteristics of (KTP) and cellulose polymers prepared by Hot-Melt 
Extrusion (HME) with and without injection of pressurized carbon dioxide (P-CO2). 
2.3. Influence of Pressurized Carbon Dioxide on drug loading of High Melting Point 
Carbamazepine and Low Molecular Weight Hydroxypropylcellulose Matrices Using Hot 
Melt Extrusion 
2.3.1. Objective 
The main objective of this research was to investigate the effect of foam like structure produced 
by pressurized carbon dioxide (P-CO2) on the drug loading and the dissolution profile of 
carbamazepine (CBZ) and low molecular weight hydroxypropylcellulose (HPC) matrices using 
hot-melt extrusion techniques. 
2.4. Dissolution Enhancement of the Psychoactive Natural Product- Piperine Using Hot 
Melt Extrusion Techniques 
2.4.1. Objective 
The aims of the current research project were to: 
1. Investigate the efficiency of various polymers to enhance the solubility and dissolution rate 
of piperine using hot melt extrusion techniques. 
2. Increase the systemic absorption of piperine via enhancing its permeability. 
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CHAPTER III 
Effect of Pressurized Carbon Dioxide on the Physico-Mechanical Properties of Hot Melt 
Extruded Cellulose Polymers 
3.1. Introduction 
Solubility is considered one of the most important factors to determine the oral bioavailability of 
any active pharmaceutical ingredient (API) [10]. Over 40% of APIs are poorly water soluble and 
result in low oral bioavailability[11]. Thus, enhancement of the solubility and oral bioavailability 
of APIs has received much interest within the pharmaceutical research community. Various 
techniques are used to overcome the poor water solubility of APIs such as salt formation, 
solubilization by cosolvents, particle size reduction, pro-drug approaches, as well as the most 
successful one to date, solid dispersion technique [10, 12] Solid dispersion is defined as “The 
dispersion of one or more active ingredients in an inert carrier matrix at solid-state’’[13]. There 
are many methods to prepare solid dispersions such as the fusion method, ball milling, solvent 
evaporation, lyophilization, hot melt extrusion (HME) and supercritical fluid methods [14-16] 
HME has received increasing attention in the pharmaceutical industry over the last few decades 
as a beneficial technique to produce solid dispersions[17]. There are many advantages of using 
HME over the conventional pharmaceutical processing methods, such as it is a relatively fast, 
continuous manufacturing process [18, 19] and it can convert an active pharmaceutical ingredient 
(API) into its amorphous state [20]. Moreover, another important advantage of HME is that no 
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solvent is required, so it is considered a “green method” to enhance the solubility and oral 
bioavailability of poorly water soluble drugs [21, 22]. However, a concern of HME is drug and 
polymer degradation due to potential high processing temperature. Thus, in case of thermo-labile 
drugs, processing aids or plasticizers might be added to reduce the viscosity and lower the 
minimum processing temperature, thus decreasing both drug and polymer degradation [23]. 
Choice of plasticizers as processing aids in HME depends on the compatibility between the drug 
and other excipients in the formulation. Use of plasticizers may affect the physico-mechanical 
properties and drug release profiles of the hot melt extrudates. Plasticizers often increase the 
elasticity and flexibility of  the extrudates [23]. Some plasticizers adversely affect the storage 
stability of pharmaceutical formulations resulting in changes within their release profiles [24]. 
It has been reported that P-CO2 can act as a reversible plasticizer and foaming agent
 [25]. CO2 is 
non-toxic, nonflammable and chemically inert in nature [26, 27]. These properties could increase 
the interest in the combination of P-CO2 and HME [28]. Previous investigations have shown that 
P-CO2 when injected during HME processing acts as a plasticizer for some pharmaceutically 
utilized polymers, such as Eudragit® E100, polyvinylpyrrolidone-co-vinylacetate 64 (PVP-VA 
64) and ethylcellulose 20 centipoise (EC 20 cps), (allowing for a decrease in their Tg) [29] and 
thus, reduction in the extrusion processing temperatures [3, 30-33]. Within the HME process, P-
CO2 changes the microscopic morphology of the extrudates to foam-like structures due to its 
expansion characteristics at the extrusion die [25, 34]. This morphological change could result in 
increasing the surface area and porosity , thereby, enhancing the milling efficiency of hot melt 
extrudates [30, 35] . In the recent past, several studies have evaluated the effect of supercritical 
CO2 on HME processing. However, limited studies have been conducted to study the effect of 
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the pressurized (subcritical) state of CO2. P- CO2 entails more advantages than supercritical CO2 
such as being more economical since no pump is required.  
Hydroxypropyl cellulose (HPC) (Figure 3-1) is non-ionic water soluble cellulose ether. It has 
many pharmaceutical applications such as an emulsion stabilizer, binder, film-former, thickener 
and drug carrier [36]. Typically, HPC extrudates may be difficult to mill due to its high elasticity 
and hygroscopicity [37].  An objective of this study is to resolve this potential issue. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Chemical structure of Hydroxypropylcellulose (HPC). 
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3.2. Materials 
Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC) and polyplasdone XL TM were obtained 
as gift samples from Ashland Inc (Wilmington, DW 19808 USA). Propylene glycol and 
Magnesium Stearate were purchased from Spectrum Chemicals (14422 S. San Pedro Street 
Gardena, CA 90248 USA). CO2 was supplied in gas cylinders (pure clean) from Airgas (902 
Rockefeller St, Tupelo, MS 38801 USA), Avicel®102 was received as a gift sample from FMC 
biopolymers (1735 Market Street, Philadelphia PA 19103 USA). Aerosil® was obtained as a gift 
sample from Evonik degussa Corporation (379 Interpace Parkway, Parsippany, NJ 07054 USA). 
All other chemicals and reagents used in the present study were of analytical grade and obtained 
from Fisher scientific (Fair Lawn, NJ 07410 USA). 
3.3. Methodology 
3.3.1. Thermogravimetric Analysis (TGA) 
TGA studies were performed for Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC) to 
determine their stability at the extrusion temperatures using a Perkin Elmer Pyris 1 TGA 
equipped with Pyris manager software (PerkinElmer Life and Analytical Sciences, 710 
Bridgeport Ave., Connecticut, USA). 
3.3.2. Hot Melt Extrusion (HME) 
The HME processes were performed using a twin-screw extruder (16 mm Prism Euro Lab, 
ThermoFisher Scientific). The extruder is divided into 10-barrel segments adjacent to the 
gravimetric feeder. Thermo Fisher Scientific standard screw configuration was used for this 
study, which consists of four conveying segments and three mixing zones and all of the injections 
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Mixing elements Conveying elements 
Zone 2 Zone 3 Zone 4 Zone 5 Zone 6 
Zone 8 Zone 9 Zone 10 Zone 7 DIE 
Feeding 
Zone 
Feed Port Feed Port 
 
Feed Port Feed Port 
  
were made through the injection port at the conveying zones of the screw configuration (Figure 
3-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: Types of screw elements and the screw configuration. 
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 All of the formulations as mentioned in (Table 3-1) were extruded at maximum torque possible. 
The screw speed was 100 rpm at a temperature range from 90-140°C and, at a feed rate of ~ 
0.7Kg/hr. The propylene glycol was injected in a barrel segment 4 using Watson-Marlow 520S 
IP31 Pump.  
 
Table 3-1: Formulation composition of HME  
 
Formulation 
 
KlucelTM                  
ELF       
(%) 
 
KlucelTM   
EF         
(%) 
 
KlucelTM     
LF          
(%) 
 
Propylene- 
glycol (PG) 
(%) 
 
 
CO2 Injection 
Zone 
K1 100 - - - - 
K2 - 100 - - - 
K3 - - 100 - - 
K4 100 - - - Zone 4 
K5 - 100 - - Zone 4 
K6 - - 100 - Zone 4 
K7 95 - - 5 - 
K8 - 95 - 5 - 
K9 - - 95 5 - 
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CO2 was pressurized and injected into the extruder using a high-pressure regulator connected to 
flexible stainless steel hose with armor casing. The other end of the hose was connected to the 
four-way connection, fitted with a pressure gauge, bleed valve, check valve (ball type for 
unidirectional flow of gas), with the later being connected to the injection port seating on the 
extruder in barrel segment 4 or 6 (Figure 3-3). Metering of CO2 was regulated using the regulator 
knob. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3: Schematic diagram for P-CO2 injection in hot melt extrusion processing.  
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3.3.3. Light Microscopy  
To evaluate the microscopic morphology of the extrudates with and without P-CO2 injection and, 
with the addition of 5% PG, light microscope with camera was used. Thin transverse section (TS) 
of extrudates were placed on glass slides and observed under the microscope. Photographs of TS 
samples were taken with zoom power 3x. 
3.3.4. Milling 
The hot melt extrudates were milled and passed through ASTM mesh sieve #35 using a 
comminuting mill (Fitzpatrick, Model L1A). 
3.3.5. Tabletting 
The milled extrudates were used to prepare the tablet blends using microcystalline cellulose 
(Avicel®102) as diluent, colloidal silicon dioxide (Arosil®) as flowability enhancer, 
polyplasedone XL TM as a disintegrant and magnesium stearate as a lubricant (Table 1-2). The 
tablet blends were compressed with the same compression force (1.5-1.6 kN) on a manual tablet 
press using 8 mm biconcave punch to a final tablet weighing 175mg. The tablet properties such 
as thickness, hardness and tablets percent friability were performed. A digital caliper was used to 
obtain the tablet thickness. Optimal control tablet hardness tester was used for the tablet hardness 
determination. The percent friability was calculated for each batch using a Vanderkamper 
friability tester by applying the following equation. 
 
                                    𝐹 =
𝑊1−𝑊2
𝑊1
 × 100                  (Equation 3-1) 
 
Where F is percent friability, and W1 and W2 are the initial and final tablet weights,              
respectively. 
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Table 3-2: Placebo tablet composition for non-API extrudates with and without P-CO2 
injection and physical mixture of non-extruded polymers 
Excipients % (w/w) Weight (mg/tablet) 
KlucelTM (ELF/EF/LF) 28.57 50.00 
Avicel® 102 68.00 119.00 
Aerosil® 0.57 1.00 
PolyplasdoneTM  XL 2.29 4.00 
Magnesium stearate 0.57 1.00 
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3.4. Results and Discussions 
3.4.1. Thermal Analysis 
Thermogravimetric Analysis (TGA) is a technique in which the material sample weight is 
monitored as a function of temperature. TGA is an essential laboratory tool used to determine the 
material decomposition temperature and the moisture content. The TGA data demonstrated that 
Klucel™ ELF, EF and LF depredation temperatures were about 300 oC in which the polymers 
start losing weight with increasing the temperature. From the TGA thermogram we can conclude 
that all the polymers used in this study were stable under the employed extrusion processing 
temperature (120 oC- 140 oC) which is way lower than their decomposing temperatures (Figure 
3-4). 
  
 
 
 
 
 
 
 
 
Figure 3-4: TGA thermogram of that Klucel™ ELF, EF and LF. 
Temperature (oC) 
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3.4.2. Hot Melt Extrusion 
During extrusion with P-CO2 injection, metering of CO2 was controlled using the regulator until 
the reading on the pressure gauge located at the 4-way connector was maintained between 75-150 
psi. CO2 was provided in a liquid form from a CO2 gas cylinder (pure clean). The back pressure 
from the injection port maintained the CO2 in a liquid state that further dropped the temperature 
at the injection port as low as 2°C. The injection zone should be completely filled with the 
physical mixture for the formation of the melt seals to prevent any leakage of gas from the 
extruder and allow good mixing between the materials and CO2. As described by Verreck et al., 
2007d, diffusion and dissolution of the injected P-CO2 in the polymers manifested as extremely 
foamy extrudates with the increment of die swelling accompanied by CO2 expansion at the 
terminal end of the die (Figure 3-5).  
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With P-CO2 
injection 
Without P-CO2 
injection 
Without P-CO2 
injection 
With P-CO2 
injection 
(Foamy extrudates) 
 
 
 
 
 
 
 
 
 
 
As investigated by Repka et al., HPC extrudates were more dense, flexible and hygroscopic [37]. 
While, upon injection of PG in zone 4, the extrudates were sticky and elastic. Injection of PG as a 
plasticizer reduced the extrusion processing temperature by about 30oC. However, the P-CO2 can 
also act as a plasticizer which has been previously mentioned by Lyons et al. [33]. In 
formulations of k4, k5 and k6 when P-CO2 was injected in zone 4, the processing temperature 
decreased by about 20°C as compared to the processing temperature without injecting P-CO2 
(Table 3-3).  
 
 
Figure 3-5: HME extrudates processed with and without P-CO2 injection. 
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Table 3-3: Processing parameters for hot melt extrusion process of K1- K9 
Formulation Extrusion Temp. (oC) Screw Speed (rpm) Torque (Nm) 
K1 140 100 21-22 
K2 140 100 22 
K3 140 100 20-22 
K4 
Zone 2-4 (140 oC)             
Rest of the zones (120 oC) 
100 18-18.5 
K5 
Zone 2-4 (140 oC)             
Rest of the zones (120 oC) 
100 18 
K6 
Zone 2-4 (140 oC)             
Rest of the zones (120oC) 
100 17-19 
K7 90 100 12-16 
K8 90 100 12-17 
K9 90 100 14-18 
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These findings confirmed that CO2 acts as a reversible plasticizer and escapes from the 
formulation at the end of HME processing and no more weight will be added to the formulation 
as shown by Verreck et al. [31]. Furthermore, CO2 is chemically inert, so the compatibility issue 
of other plasticizers with the polymers used in the study was avoided. The microscopical images 
of the extrudates processed with P-CO2 injection demonstrated higher surface area and porosity 
as compared to the extrudates processed without P-CO2 injection and, the one with PG injection 
(Figure 3-6).  
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Figuer 3-6: Microscopy photographs of KlucelTM (ELF, EF, and LF) extrudates with 
and without P-CO2 injection, or with PG injection (Magnification 3X). (a) ELF 
without P-CO2, (b) ELF with P-CO2, (c) ELF with PG injection, (d) EF without P-
CO2, (e) EF with P-CO2, (f) EF with PG injection, (g) LF without P-CO2, (h) LF with 
P-CO2, (i) LF with PG injection. 
 
a
  a 
d 
c b 
h g 
f e 
i 
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HPC extrudates typically are very difficult to be milled and a freezing process is required before 
the milling procedure [38]. Because of the high flexibility and hygroscopicity of the extrudates 
with PG injection, milling failing occurs due to the shutdown of the Fitzmill as a result of 
generation of maximum torque (Figure 3-7). 
 
 
 
 
 
 
 
 
 
 
The phenomenon of milling failing on these extrudates with PG injection could not be improved 
even when the freezing process is used before the milling. Milling process is an essential step in 
the pharmaceutical industries and failing of this step will prevent any further processing into 
suitable dosage forms. A significant enhancement of the milling efficiency of extrudates with P-
CO2 injection was observed. The milling efficiency was determined by the torque value of the 
Figure 3-7: Failed milling of KlucelTM (ELF, EF, and LF) extrudates with PG 
injection. 
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Fitzmill. As mentioned by Verreck et al.[30] these processing properties of the materials would 
provide numerous benefits during manufacturing of various solid dosage forms such as tablets 
and capsules. 
Jeong et al. has shown that there is a lowering in bulk density of extrudates in the presence of P-
CO2 injection [39]. Our results showed that foamed milled extrudates exhibited lower bulk 
density and tap density as compared to the extrudates without P-CO2 injection, due to an increase 
in porosity and surface area of the extrudates (Table 3-4).  
 
Table 3-4: Bulk and tap density of milled extrudates with and without P-CO2 injection 
(g/mL) ±SD (n=3) 
Sample name 
Without P-CO2 injection With P-CO2 injection 
Bulk density Tap density Bulk density Tap density 
KlucelTM ELF 0.265± 0.009 0.366± 0.011 0.154± 0.003 0.241± 0.002 
KlucelTM EF 0.294± 0.007 0.441± 0.008 0.131± 0.002 0.213± 0.005 
KlucelTM LF 0.304± 0.013 0.435± 0.004 0.191± 0.004 0.227± 0.007 
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3.4.3. Tablets evaluation 
The bulk density and tap density of the tablet blends prepared with extrudates processed with P-
CO2 injection was lower as compared to the other blends without P-CO2 injection and 
unprocessed physical mixtures, as a result of the foam extrudates (Table 3-5). 
 
Table 3-5: Bulk and Tap density of placebo tablet blends (g/mL) 
 
Sample name 
Physical mixture Without P-CO2 
injection 
With P-CO2 injection 
Bulk 
Density 
Tap 
Density 
Bulk 
Density 
Tap 
Density 
Bulk 
Density 
Tap 
Density 
KlucelTMELF 0.393 0.492 0.366 0.473 0.303 0.419 
KlucelTM EF 0.395 0.510 0.385 0.485 0.303 0.413 
KlucelTM LF 0.407 0.516 0.393 0.492 0.354 0.462 
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The evaluation of all Klucel™ ELF, EF and LF placebo tablets showed that the tablet weight 
variations of all the formulations were acceptable with very low standard deviations (SD < 1.0). 
In case of the tablets prepared with foamed extrudates, tablet hardness was enhanced by 22%- 
33% compared to those prepared by extrudates without P-CO2 injection and unprocessed 
physical mixtures (Figure 3-8). Tablet friability was evaluated for all of the formulations and the 
results showed lowering in the % friability of tablets prepared with foamy extrudates (less than 
0.3%) as compared to the other tablet formulations (0.6%-1.7%) (Figure 3-9). These results 
indicated good binding properties and compressibility of foamy extrudates. 
 
  
 
 
 
 
 
 
 
 
 
Figure 3-8: Hardness in (kp) of Klucel TM ELF/EF/LF placebo tablets. 
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Figure 3-9: % Friability of Klucel TM ELF/EF/LF placebo tablets. 
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3.5. Conclusion 
P-CO2 acted as a temporary plasticizer for Klucel
TM ELF, EF, and LF when injected in zone 4 
during HME processing, allowing reduction in extrusion temperatures. Whereas, when the P-CO2 
was injected in zone 6 the reduction in extrusion temperature was not feasible. Thus, the zone in 
which P-CO2 is injected plays a significant role in melt extrusion processing. The microscopic 
morphology of the extrudates with P-CO2 injection was changed to a foam-like structure, which 
increases their surface area and porosity. Moreover, the milling efficiency of all extrudates 
processed with P-CO2 was enhanced, which may be beneficial for optimizing the manufacturing 
of solid dosage forms. A combination of P-CO2 and HME improved the tablet properties (higher 
hardness & lower friability) indicating good binding properties and compressibility of the blends. 
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CHAPTER IV 
Influence of Pressurized Carbon Dioxide on Ketoprofen-Incorporated Hot-Melt Extruded 
Low Molecular Weight Hydroxypropylcellulose 
4.1. Introduction: 
HME is commonly used in the pharmaceutical industry for solubility enhancement applications. 
Carbon dioxide is non-toxic, non-flammable, and chemically inert [26, 27]. It was observed in 
earlier study that hot-melt extrusion processing assisted with P-CO2 increased porosity and the 
surface area of the extrudates and changed the macroscopic morphology to a foam-like structure 
and furthermore enhanced the milling efficiency. Additionally, the drug dissolution rates 
increased significantly up on foaming extrudates structures. In this current research study, the 
main objective was to evaluate the effect of P-CO2 on ketoprofen (KTP) and HPC polymers 
using HME techniques. The model drug KTP (Figure 4-1) is a non-steroidal anti-inflammatory 
agent[40] and, it is crystalline in nature with poor water solubility [41]. It is conventionally 
formulated as an oral dosage form [42]. It is thermally stable with a melting point of 
approximately 95oC and “burns out” over a temperature range of 235-400oC [43]. Indeed the 
literature has recently reported that hot melt extudates of KTP and HPC has demonstrated poor 
milling efficiency [38]. In order to solve these underlining issues, in the present study we 
investigated the effect of P-CO2 on the physico-mechanical properties as well as the release 
profiles of KTP and HPC extrudates produced using HME techniques. 
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4.2. Material  
Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC) and polyplasdone XL TM were obtained 
as gift samples from Ashland Inc. (Wilmington, DW 19808 USA). Ketoprofen was purchased 
from Parchem-Fine & specialty chemicals (415 Huguenot St, New Rochelle, NY 10801 USA). 
CO2 was supplied in gas cylinders (pure clean) from Airgas (902 Rockefeller St, Tupelo, MS 
38801 USA), Avicel®102 was received as a gift samples from FMC biopolymers (1735 Market 
Street, Philadelphia PA 19103 USA). Flow lac® 90 was received as a gift samples from Meggle 
USA Inc. (50 Main street, White Plains, NY 10606 USA). Syloid® was received from W. R. 
Grace & Co.- Conn (7500 Grace Drive, Columbia, MD 21044 USA). Magnesium Stearate was 
purchased from Spectrum Chemicals (14422 S. San Pedro Street Gardena, CA 90248 USA).  All 
other chemicals and reagents used in the present study were of analytical grade and obtained 
from Fisher scientific (Fair Lawn, NJ 07410 USA). 
 
Figure 4-1: Chemical structure of Ketoprofen (KTP) 
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4.3. Method 
4.3.1. Thermal Analysis 
4.3.1.1. Thermogravimetric Analysis (TGA) 
TGA studies were performed for KTP and polymers used in this study to determine their stability 
at the extrusion temperatures using a Perkin Elmer Pyris 1 TGA equipped with Pyris manager 
software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA.  
4.3.1.2. Differential Scanning Calorimetry (DSC) 
DSC was obtained using Perkin Elmer Pyris 1 DSC equipped with Pyris manager software 
(PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA). 
Approximately 2-4 mg of KTP, physical mixtures or extrudates were heated from 30°C to 200 
°C at heating rate of 10°C/min.  
4.3.2. Physical mixture 
KTP and Klucel TM LF, EF and ELF hydroxypropylcellulose (HPC) polymers were sieved using 
ASTM #35 mesh. Physical mixture of 15% w/w KTP with each polymer were mixed using a V-
Shell blender for 10 minutes. Tree samples from each physical mixture were analyzed for blend 
drug content and uniformity. 
4.3.3. Hot Melt Extrusion 
The physical mixture blends (Table 4-1) were extruded with or without P-CO2 injection using a 
twin-screw extruder (16 mm Prism EuroLab, ThermoFisher Scientific) (Figure 4-2) at screw 
speeds of 100 rpm (temp range: 90–140°C) (Table 4-2) P-CO2 was injected into the extruder as 
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described previously in chapter I using a high-pressure regulator connected with flexible 
stainless steel armor-cased hosing. The other end of the hose was connected to the injection port 
seating on segment 6 of the extruder barrel (Figure 4-3). 
 
Table 4-1: Formulation composition of HME  
Formulation KTP (%) 
KlucelTM 
ELF (%) 
KlucelTM   EF 
(%) 
KlucelTM LF 
(%) 
CO2 injection 
zone 
K10 15 85 - - - 
K11 15 - 85 - - 
K12 15 - - 85 - 
K13 15 85 - - Zone 6 
K14 15 - 85 - Zone 6 
K15 15 - - 85 Zone 6 
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Table 4-2: Processing parameters for hot melt extrusion process of K10-K15   
Formulation Extrusion Temp. (oC) Screw Speed (rpm) Torque (Nm) 
K10 110 75 9-14 
K11 110 75 9-12 
K12 110 75 11-13 
K13 100 75 8-9 
K14 100 75 9-10 
K15 100 75 9-12 
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Figure 4-2: 16 mm Prism EuroLab, ThermoFisher Scientific. 
Figure 4-3: P-CO
2
 injection port. 
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4.3.4. Microscopical images 
Microscopy photographs were performed for thin transverse section (TS) of all extrudates using 
light microscope with camera (Nikon SMZ-U). Photographs of TS samples were taken with 
zoom power 3x. 
4.3.5. Milling 
All the extrudates were milled and sieved through ASTM #35 mesh using a comminuting mill 
(Fitzpatrick, Model L1A). 
4.3.6. High-Performance Liquid Chromatography (HPLC) 
All samples were analyzed using a Waters HPLC equipped with Empower software to analyze 
the data. HPLC consisted of a Water 600 binary pump, Waters 2489 UV/detector, and Waters 
717 plus autosampler (Waters Technologies Corporation, 34 Maple St., Milford, MA 0157). The 
column used was phenomenex luna C18 (5µ, 250 mm × 4.6 mm). The mobile phase constituted 
of  acetonitrile/20 mMol phosphate buffer, 55:45 (%v/v) at pH 4 [38, 44] at a flow rate of 1 
mL/min and injection volume of 20 μl. The UV detector wavelength for KTP detection was set at 
256 nm. 
4.3.7. In Vitro Drug Release 
Extrudates equivalent to 25 mg KTP were filled in HPMC capsules and in vitro drug release 
profiles were performed using a USP type II dissolution apparatus. The dissolution media was 
1000 mL 0.05 M phosphate buffer pH 7.4 and, was maintained at 37 oC. A sample volume of 2 
mL were taken at time points 10, 20, 30, 45, 60 min. [45], filtered and analyzed using HPLC and 
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2 mL of fresh dissolution media were added back to the dissolution vessel at each time point. 
The release profiles of 25 mg KTP tablets were obtained in the same conditions. 
4.3.8. Tabletting 
4.3.8.1. Tablet preparation 
The milled extrudates were used to prepare the tablet blends using microcystalline cellulose 
(Avicel®102) or lactose (flow lac® 90) as diluent, silicon dioxide (Syloid®) as flowability 
enhancer, polyplasedone XL TM as a disintegrant and magnesium stearate as a lubricant (Table 4-
3). The 25 mg strength tablets were compressed with the same compression force (1.5-1.6 kN) 
on a manual tablet press using 10 mm biconcave punch to a final tablet weight of 350 mg. 
 
Table 4-3: KTP tablet composition of extrudates with and without P-CO2 injection 
Excipients % (w/w) Weight (mg/tablet) 
KTP 7.14 25.00 
KlucelTM (ELF/EF/LF) 40.46 141.66 
Avicel® 102 24.60 86.10 
Flowlac 90 12.30 43.05 
Syloid® 10.00 35.00 
PolyplasdoneTM  XL 5.00 17.5 
Magnesium stearate 0.50 1.75 
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4.3.8.2. Tablet Evaluation 
Tablets were evaluated for thickness, hardness, friability, and disintegration time as well as 
release profiles. 
4.3.9. Moisture Analysis 
To evaluate the moisture content of the extrudates , OHOUS MB45 moisture analyzer  was used. 
6-7 gm. of the extrudates placed in the sample pan and inserted in the sample chamber and then 
heated to 110 oC for 15 minutes. Samples weight loss of drying was recorded as well as the % of 
the moisture. 
4.3.10. Stability Study 
All KTP/Klucel TM ELF, EF and LF extrudates with and without P-CO2 injection were sealed in 
glass bottles and stored at 25oC/60% RH for three months. Recrystallization assessments were 
determined by DSC. 
4.4. Results and discussion  
4.4.1. Thermal Analysis 
TGA data demonstrated that all formulations utilized in this study were stable under the 
employed processing temperature (Figure 4-4).  
Differential Scanning Calorimetry, or DSC, is a thermal analysis technique evaluates how a 
material’s heat capacity (Cp) is changed by temperature. The information generate by DSC is 
used to understand amorphous and crystalline behavior of the polymer and drug in the 
pharmaceutical industries. The DSC data showed that ketoprofen melting peaks at 90oC 
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disappeared for all of the milled extrudates with and without P-CO2 injection, which indicated 
the conversion of the crystalline form into the amorphous form. All milled extrudates remained 
in an amorphous form at the end of the last time point after 3 months of storage at 25oC/60% RH 
(Figure 4-5).  
 
 
 
 
 
 
Figure 4-4: TGA thermogram of that Ketoprofen and Klucel™ ELF, EF and LF. 
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Figure 4-5: DSC thermogram of Ketoprofen, physical mixture and extrudates with and 
without P-CO2 injection at 0, 1, 2, 3 months. 
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4.4.2. Hot Melt Extrusion 
Hot melt extrusion processes were performed using 16 mm Prism Euro Lab, Thermo Fisher 
Scientific) with Thermo Fisher Scientific standard screw configuration. The injections were made 
through the injection port at the conveying zone of the screw configuration. The resulted 
extrudates processed without P-CO2 injection were dense, opaque, elastic and sticky extrudates 
with all polymeric matrices. While other extrudates which processed with P-CO2 were foamy and 
porous extrudates (Figure 4-6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6: KTP/ Klucel
TM
 extrudates with and without P-CO
2 
injection. 
Foamy extrudates 
with P-CO2 injection 
Regular extrudates 
without P-CO2 injection 
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The microscopical images of the TS sections of different extrudates showed that the porosity of 
the extrudates processed with P-CO2 was increased (Figure 4-7). This change in the extrudates 
morphological properties was due to the expansion of the carbon dioxide at the extrusion die.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Without CO2 With CO2 
Figure 4-7: Microscopy photographs of TS sections of a) 15% KTP& Klucel
TM
 ELF 
b) 15% KTP& Klucel
TM
 EF, and c) 15% KTP& Klucel
TM
 EF extrudates with and 
without P-CO2
 
injections (Magnification 3X). 
a 
b 
c 
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As observed previously, the milling efficiency of the extrudates processed with P-CO2 was 
enhanced compared with extrudates processed without P-CO2 (Figure 4-8). The foamed milled 
extrudates exhibited lower bulk density and tap density as compared to the extrudates processed 
without P-CO2 injection, due to an increase in porosity and surface area of the extrudates (Table 
4-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Dry ice + Milling 
Milling 
Milled extrudates 
Without P-CO2 injection 
With P-CO2 injection 
Figure 4-8: Milling processing and milled extrudates. 
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Table 4-4: Bulk and tap density of milled extrudates with and without P-CO2 injection 
(g/mL) 
 
Sample name 
Without P-CO2 injection With P-CO2 injection 
Bulk density Tap density Bulk density Tap density 
KTP/ KlucelTM 
ELF 
0.382± 0.012 0.434± 0.008 0.175± 0.001 0.270± 0.003 
KTP/ KlucelTM 
EF 
0.286± 0.009 0.373± 0.007 0.150± 0.001 0.235± 0.005 
KTP/ KlucelTM 
LF 
0.325± 0.013 0.415±0.011 0.145± 0.002 0.240± 0.006 
 
4.4.3. Drug Content 
HPLC analysis confirmed that the drug content uniformity of KTP in all formulations were 
acceptable and within the range of 98-105%. These results indicated good homogeneity of all 
formulations.  
4.4.4. In-vitro Drug Release  
The in vitro drug release concedes as an important aspect in drug development that reflect drug 
in vivo performance [46]. The in vitro dissolution profiles were performed to evaluate the KTP/ 
Klucel™ ELF, EF and LF release behavior of milled extrudates with or without P-CO2 injection 
as well as unprocessed physical mixtures. Plots of time vs. % drug release, which is the average 
of three replicates, were used as dissolution profiles for different formulations (Figures 4-9, 4-10, 
and 4-11). These profiles demonstrated a significant improvement of KTP release in the presence 
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of P-CO2 injection as compared to the other formulations. The release enhancement was 
observed as a direct result of the foam-like structure and high surface area of those extrudates 
with P-CO2 injection[47-50].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9: Dissolution profiles of KTP/KlucelTM ELF extrudates with and without P-
CO2 injection and physical mixture (pH 7.4 phosphate buffers, USP App II, 50 
rpm/37oC).  
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Figure 4-11: Dissolution profiles of KTP/KlucelTM LF extrudates with and without P-
CO2 injection and physical mixture (pH 7.4 phosphate buffers, USP App II, 50 
rpm/37oC).  
 
Figure 4-10: Dissolution profiles of KTP/KlucelTM EF extrudates with and without P-
CO2 injection and physical mixture (pH 7.4 phosphate buffers, USP App II, 50 
rpm/37oC).  
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4.4.5. Tablet Evaluation 
The tablet blends prepared with extrudates processed with P-CO2 injection showed lower bulk 
and tap density compared to other tablet blends due to formation of foam like structure as well as 
increase porosity and surface area of these extrudates (Table 4-5). 
 
Table 4-5: Bulk and Tap density of KTP tablet blends (g/mL) 
 
Sample Name 
Physical mixture 
Without P-CO2 
injection 
With P-CO2 
injection 
Bulk 
Density 
Tap 
Density 
Bulk 
Density 
Tap 
Density 
Bulk 
Density 
Tap 
Density 
KTP/ KlucelTM 
ELF 
0.40 0.61 0.46 0.66 0.35 0.49 
KTP/ KlucelTM 
EF 
0.39 0.57 0.44 0.59 0.33 0.47 
KTP/ KlucelTM 
LF 
0.39 0.57 0.44 0.59 0.33 0.47 
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Tablets were successfully prepared (Figure 4-12) and showed that the drug content of all 
formulations ranged from 96-110% indicating good drug uniformity of all formulations. 
Furthermore, tablet weight variations of all the formulations were very low with standard 
deviations (SD < 1.0). 
 
 
 
 
 
 
 
 Tablets processed using P-CO2 assisted extrudates exhibited higher hardness (Figure 4-13) and 
lower % friability (Figure 4-14) due to good binding properties and compressibility of the 
extrudates, as compared to those not processed with P-CO2. To understand this phenomenon, 
moisture content of the extrudates was performed. Table 4-6 showed the moisture content of the 
extruades with and without P-CO2 injection. The results clearly demonstrated that extrudateds 
processed with P-CO2 having more moisture than extrudateds processed without P-CO2. This 
observation explained the increases of the tablet hardness in case of using blends of extrudateds 
processed with P-CO2. 
 
Figure 4-12: Ketoprofen tablets.  
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Figure 4-13: Hardness in (kp) of KTP/Klucel TM ELF/EF/LF tablets, with and 
without P-CO2 injection and physical mixture.  
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Figure 4-14: % Friability of KTP/Klucel TM ELF/EF/LF tablets, with and without 
P-CO2 injection and physical mixture.  
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Table 4-6: Moisture content of KTP/ KlucelTM ELF, EF, and LF 
Sample Name 
LOD% 
Without P-CO2 With P-CO2 
KTP/ KlucelTM ELF 0.53 0.88 
KTP/ KlucelTM EF 0.69 0.91 
KTP/ KlucelTM LF 0.56 1.54 
 
The tablets were also subjected to in vitro dissolution studies of KTP/ KlucelTM EF tablets with 
and without P-CO2 injection. No significant differences were observed in the drug release 
profiles of tablets with and without P-CO2 extrudates (Figure 4-15). These results indicate that 
the dissolution improvement of extrudates processed with P-CO2 was due to the high surface 
area and porosity, as compared to the extrudates without P-CO2 injection. Whereas, when these 
extrudates were compressed into tablets, the compression force reduced the surface area of the 
foamy extrudates which eliminates the dissolution improvements utilizing P-CO2 injections. 
Therefore, there was no effect of P-CO2 injection on the tablet release profile. 
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Figure 4-15: Dissolution profiles of KTP/KlucelTM EF tablets with and without P-CO2 
injection (pH 7.4 phosphate buffers, USP App II, 50 rpm and 37oC). 
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4.5. Conclusion 
It has been observed that Hot-melt extrusion processing assisted with P-CO2 increased porosity 
of the KTP/ KlucelTM ELF, EF and LF extrudates and changed the macroscopic morphology to a 
foam-like structure due to expansion of the carbon dioxide at the extrusion die. These properties 
allowed enhancement of the milling efficiency of the extudates assisted with P-CO2. 
Furthermore, the extrudates processed with P-CO2 injection demonstrated an enhancement of 
KTP release as compared to the physical mixtures and the extrudates processed without P-CO2 
injection, due to the increase in the surface area and porosity. However, there was no significant 
difference in the drug release profiles of tablets prepared with or without CO2 extrudates after the 
compression process, which indicates that P-CO2 injection does not alter the drug release profiles 
of tablets.  Alternatively, it instead improves the processing properties of the tablets. P-CO2 
utilized in HME processing may exhibit similar benefits of supercritical CO2 while avoiding 
some of the disadvantages experienced when utilized at the supercritical fluid level. 
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CHAPTER V 
Influence of Pressurized Carbon Dioxide on drug loading of High Melting Point 
Carbamazepine and Low Molecular Weight Hydroxypropylcellulose Matrices Using Hot 
Melt Extrusion 
5.1. Introduction 
Carbamazepine (CBZ) (Figure 5-1) is an anticonvulsant drug used in the treatment of epilepsy, 
bipolar disorder and specific analgesic for trigeminal neuralgia [51, 52]. Biopharmaceutics 
Classification System categorized CBZ as class II with poor water solubility and good 
permeability [53]. It has prolonged absorption rate due to its lower dissolution rate [54]. 
However, CBZ crystalizes under at least four polymorphic crystal forms which include; Triclinic 
(Form I), Trigonal (Form II), P-Monoclinic (Form III), C-Monoclinic (Form IV). Variations in 
dissolution rate and absorption rate of CBZ have been reported due to the presence of the drug in 
different crystalline forms [55]. To overcome this issue, CBZ solid dispersion formulations were 
prepared by different methods to produce uniform and stable CBZ solid dispersion and to 
minimize the absorption variability. Zerrouk et al used fusion and crystallization to prepare the 
solid dispersion of CBZ with PEG 6000 and observed the ability of PEG 6000 to enhance the 
CBZ solubility [56]. Soluplus and polyvinylpyrrolidone (PVP/ VA 64) were used as polymeric 
carriers to prepare CBZ solid dispersion via HME process [53, 57]. However, a concern of HME 
is the limitation of the drug loading due to drug-polymer miscibility. In a previous study, we 
investigated the effect of P-CO2 on the physico-mechanical properties as well as the drug release 
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profile using HME process. Successfully, foamed extrudates were prepared with high surface 
area and enhanced drug release profiles [58]. Elizondo et al observed that P-CO2 can be used to 
prepare highly loaded antibiotic nanostructured PVM/MA matrices [59]. Considering these 
observations, it would be interesting to investigate the effect of P-CO2 on the drug loading and 
the dissolution profiles of CBZ processed by HME.  
 
 
 
 
 
 
 
 
5.2. Material 
Klucel™ ELF hydroxypropylcellulose (HPC) was received as gift samples from Ashland Inc 
(Wilmington, DW 19808 USA). CBZ was purchased from AFINE Chemicals Limited (Sandun 
Town, Hangzhou 310030 China). CO2 was supplied in gas cylinders (pure clean) from Airgas 
(902 Rockefeller St, Tupelo, MS 38801 USA). All other chemicals and reagents used in the 
present study were of analytical grade and obtained from Fisher scientific (Fair Lawn, NJ 07410 
USA). 
Figure 5-1: Chemical structure of Carbamazepine (CBZ). 
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5.3. Method 
5.3.1. Thermal Analysis 
5.3.1.1. Thermogravimetric Analysis (TGA) 
TGA studies were performed for CBZ and Klucel TM ELF to determine their stability at the 
extrusion temperatures using a Perkin Elmer Pyris 1 TGA equipped with Pyris manager software 
(PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA). 7-10 mg. 
of the sample was weighed and heated from 30°C to 400 °C at heating rate of 20°C/min under 
nitrogen purging. 
5.3.1.2. Differential Scanning Calorimetry (DSC) 
DSC was performed to evaluate the drug polymer miscibility at different drug loading as well as 
the physical state of the all extrudates using Perkin Elmer Pyris 1 DSC equipped with Pyris 
manager software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, 
USA). Approximately 2-4 mg of CBZ, physical mixtures or extrudates were heated from 30°C to 
230°C at heating rate of 10°C/min. DSC data are also used to evaluate the % crystallinity of CBZ 
in the extruded formulation. 
5.3.2. Hot Melt Extrusion (HME) 
CBZ and Klucel TM ELF hydroxypropylcellulose (HPC) polymers were sieved using ASTM #35 
mesh. Physical mixtures of 20-50% w/w CBZ with Klucel TM ELF (Table 5-1) were mixed 
using a V-Shell blender for 10 minutes. Three samples from each physical mixture were 
analyzed for blend drug content and uniformity. The resulting blends were extruded with or 
without P-CO2 injection using a twin-screw extruder (16 mm Prism EuroLab, ThermoFisher 
Scientific) at screw speeds of 100-120 rpm and temperature range 110–130°C. P-CO2 was 
injected at 125-175 psi into the extruder using a high-pressure regulator connected with flexible 
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stainless steel, armor-cased hosing. The other end of the hose was connected to the injection port 
seating on segment 6 of the extruder barrel. All of the extrudates were milled and sieved through 
ASTM #35 mesh using a comminuting mill (Fitzpatrick, Model L1A). 
 
Table 5-1: CBZ formulation composition of HME  
 
 
 
 
Formulation CBZ (%) KlucelTM ELF(%) 
CO2 injection 
Zone 
CO2 Pressure 
(PSI) 
C1 20 80 - - 
C2 20 80 Zone 6 175 
C3 30 70 - - 
C4 30 70 Zone 6 150 
C5 40 60 - - 
C6 40 60 Zone 6 150 
C7 50 50 - - 
C8 50 50 Zone 6 125 
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5.3.3. Density 
Bulk and tap density were performed for all extrudates as well as for physical mixtures. True 
density was measured using Micromeritics AccuPyc II1340 Gas Pycnometer, where the samples 
were measured by helium displacement methods. The principle of this operation is to seal the 
known volume sample in the instrument compartment then the helium as an inert gas is inserted, 
and then helium molecules rapidly fill the pores; only the solid phase of the sample displaces the 
gas. Dividing this volume into the sample weight gives the gas displacement density. 
5.3.4. Surface Area 
Surface areas of all milled extrudates with and without CO2 injection were evaluated using 
Micromeritics, Gemini VII. 2-3 gm. of milled extrudates were placed in the sampling tube and 
the reference sample was used to calibrate the analysis to produce continued accuracy of results. 
Before analysis start, each sample was placed under vacuum to remove the moisture. The 
nitrogen adsorption-desorption isotherms of the samples were obtained at liquid nitrogen 
temperature (-195 Co). The specific surface area of the samples was obtained by means of the 
standard method of Brunauer Emmett-Teller (BET). 
5.3.5. Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy (SEM) was used to evaluate the morphology of the extrudates 
with and without P-CO2 injection. Samples were mounted on adhesive carbon pads placed on 
aluminum then they sputter coated with gold using a Hummer® 6.2 sputtering system (Anatech 
LTD, Springfield, VA) in a high vacuum evaporator. A JEOL JSM-5600 scanning electron 
microscope operating at an accelerating voltage of 10kV was used for imaging.   
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5.3.6. High-Performance Liquid Chromatography (HPLC) 
All samples analyses were performed on a Waters HPLC and Empower software was used to 
analyze the data. HPLC system consists of Waters e2695 separation Module and Waters 2489 
UV/Visible detector (Waters Technologies Corporation, 34 Maple St., Milford, MA 0157). A 
Phenomenex luna C18 (250 mm × 4.6 mm, 5µ) coulmn was used. The mobile phase constituted 
of 65:35:0.1 (%v/v) Methanol: Water: Acetic acid at flow rate of 1 mL/ min and injection 
volume of 20 µl. The UV detector wavelength for CBZ detection was set at 285 nm. 
 
5.3.7. In-Vitro Drug Release  
Extrudates equivalent to 50 mg CBZ were filled in HPMC capsules. The in vitro drug release 
profiles were performed using a USP type II dissolution apparatus. The dissolution medium was 
900 mL water and, was maintained at 37 oC with paddle rotation speed of 100 rpm. A sample 
volume of 2 mL was taken at time points 10, 20, 30, 45, 60, 90 and 120 min., filtered and 
analyzed using HPLC and 2 mL of fresh dissolution medium were added back to the dissolution 
vessel at each time point to maintain the dissolution medium volume. 
To understand the CBZ release results, data observed from in-vitro release study were used to 
calculate Dissolution Efficiency (DE) and Mean Dissolution Time (MDT) of the all formulation 
as a model independent method to compare the drug release profile of the extrudates with and 
without P-CO2 injection. KinetDS 3.0 software was used to calculate DE and MDT [60] using the 
following equations.  
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                                𝐷𝐸 =
∫ 𝑄 𝑑𝑡
𝑡
0
𝑄100×100
× 100                                                   (Equation 5-1) 
Where: 
Q – amount (%) of drug substance released at the time t 
t- time 
Q100 – maximum amount of drug released (= 100%) 
                                  𝑀𝐷𝑇 =
∑ 𝑡𝑗
𝐴𝑉×∆𝑄𝑗
𝑛
𝑗=1
∑ ∆𝑄𝑗
𝑛
𝑗=1
                                                     (Equation 5-2)  
Where: 
ΔQ = Q(t) - Q(t-1) 
tj
AV= (ti + ti-1)/2 
n – amount of time points 
Similarity factors (f2) were also calculated using (equation 5-3) to evaluate the effect of P-CO2 on 
the drug release. 
          𝑓2 = 50 × log {[1 + (1/𝑛) ∑ 𝑊𝑗 |𝑅𝑗 − 𝑇𝑗|
2𝑛
𝑗=1 ]
−0.5
× 100}                    (Equation 5-3)       
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5.4. Results and Discussion 
5.4.1. Thermal Analysis 
TGA data of CBZ, KlucelTM ELF and physical mixture did not show any sign of degradation 
until reaching approximately 250 oC and 300 oC for CBZ and KlucelTM ELF respectively. At 
those temperatures, the samples weight decreased by elevation the temperature. These results 
indicate that all prepared formulations were stable under the utilized processing temperatures 
(Figure 5-2). Additionally, TGA data also showed that KlucelTM ELF exhibited around 3% 
moisture uptake. 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: TGA thermogram of carbamazepine (CBZ) and Klucel
TM
 ELF. 
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DSC analysis was performed to determine the miscibility of CBZ/KlucelTM ELF in different drug 
load as well as evaluate the physical state of the CBZ in all extrudates prepared in this study. The 
DSC thermogram showed the CBZ endotherm melting peaks at 190oC. On the other hand, the 
physical mixtures showed a slight melting point depression of CBZ in the presence of the Klucel 
TM ELF, indicating its miscibility in the polymeric matrix (Figure 5-3). DSC data of the 
extrudates exhibit the disappearance of the endothermic melting peak of CBZ for all extrudates 
with and without P-CO2 injection except for C7 and C8. The absence of the CBZ endothermic 
melting peak indicates the formation of amorphous solid dispersion (Figure 5-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5-3: DSC thermogram of CBZ/ Klucel
 TM ELF physical mixtures showing the 
drug- polymer miscibility at different drug loading.   
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Figure 5-4: DSC thermogram of 20%, 30%, 40% and 50% of CBZ/ Klucel TM  ELF 
extrudates with and without P-CO2 injection  as well as pure CBZ. 
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DSC data are also used to determine the % crystallinity of CBZ in C7 and C8 formulation using 
the following equation  
 
Crystallinity (%) = [ΔHExtrudate/ (ΔHCBZ × w %)] ×100                       (Equation 5-4) 
 
The DSC thermogram (Figure 5-5) showed that ΔH of the CBZ is 102.402 J/g and the w% of the 
formulations were calculated depending on the drug content results. There was no significant 
different between the % crystallinity of C7 and C8 (approximately 23%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5: DSC thermogram showing the ΔH values of 50% CBZ/ Klucel TM  ELF 
extrudates with and without P-CO2 injection  as well as pure CBZ.  
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5.4.2. Hot Melt Extrusion (HME) 
The extrusion processing parameters were set depending on the TGA results and the feasibility 
and processability of the physical mixtures used in this study (Table 5-2). The twin-screw 
extruder (16 mm Prism EuroLab, ThermoFisher Scientific) consists of ten segments and an 
extrusion die. The screw configuration used in this study was Thermo Fisher Scientific standard 
cofiguration which consists of four conveying segments and three mixing zones and all of the 
injections were made through the injection port at the conveying zones of the screw 
configuration. The carbon dioxide was injected in the extruder using a high-pressure regulator 
connected with flexible stainless steel hose with armor casing. The other end of the hose was 
connected to the four-way connection, fitted with a pressure gauge, bleed valve, check valve 
(ball type for unidirectional flow of gas), with the later being connected to the injection port 
seating on the extruder in barrel segment 6. Before the injection of P-CO2, all the extruder barrel 
segments were filled with melted physical mixture to form melt seal and prevent the escaping of 
CO2 from the feeding zone. 
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Table 5-2: Processing parameters for hot melt extrusion process of C1-C8 
 
Formulation Extrusion Temp. (oC) Screw Speed (rpm) Torque (Nm) 
C1 130 100 9 
C2 130 100 7 
C3 110 100 8-9 
C4 110 100 6-8 
C5 110 100 9-12 
C6 110 100 9-10 
C7 120 100 14-18 
C8 120 100 8 
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With CO2 injection 
Without CO2 injection 
The exrudates without P-CO2 were dense and opaque, also having plastic morphology. On the 
other hand, the morphology of all extudates processed with P-CO2 were changed to a foam like 
structure (Figure 5-6) due to the carbon dioxide expansion exiting at the terminal end of the die. 
The torque values of the extruder were decreased with the formulations processed with P-CO2 
injection compared with the formulations without P-CO2 injection. This observation indicating 
the plasticization effect of carbon dioxide and prove the decrease in the glass transition 
temperature (Tg) of the blends processed with P-CO2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6: Photographic picture of CBZ /Klucel
TM
 ELF extrudates with and without 
P-CO
2
 injection. 
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The milling efficiency of formulations C2, C4, C6 and C8 were higher than the milling efficiency 
of formulations C1, C3, C5 and C7. This result was concluded by the torque values of the 
comminuting mill (Fitzpatrick, Model L1A).  
5.4.3. Density 
True density was evaluated using AccuPyc II1340, Micromeritics to all formulations, C1-C8. 
There are negligible differences in the true density values of the extrudates with and without CO2 
injection indicating no chemical change in the nature of the CBZ/KlucelTM. This result confirmed 
that CO2 is an inert material and there is no interaction between CO2 and CBZ/Klucel
TM 
formulations. On the other hand, there was a decrease in the bulk and tap densities of the 
formulations processed with CO2 injection (C2, C4, C6, C8) than those processed without CO2 
(C1, C3, C5, C7) as a direct result of the formation of foamy like structure extudates in case of 
CO2 injection as well as increase in the pore size of those extrudates. Table 5-3 displayed that the 
bulk density of formulations (C2, C4, C6, C8) are lower than formulations (C1, C3, C5, C7) by 23-
43%, While, the tap density lowered by 16- 35%. 
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Table 5-3: Bulk and tap density of CBZ /KlucelTM ELF with and without P-CO2 injection ± 
Standard deviation n=3 
Sample Name Bulk Density Tap Density 
20% CBZ/ELF  PM 0.436 ± 0.013 0.578 ± 0.008 
C1 0.356 ± 0.009 0.470 ± 0.006 
C2 0.205 ± 0.008 0.307 ± 0.005 
30% CBZ/ELF  PM 0.335 ± 0.001 0.554 ± 0.032 
C3 0.377 ± 0.011 0.490 ± 0.002 
C4 0.262 ± .001 0.367 ± 0.001 
40% CBZ/ELF  PM 0.452 ± 0.003 0.637 ± 0.004 
C5 0.469 ± 0.003 0.616 ± 0.011 
C6 0.325 ± 0.006 0.449 ± 0.010 
50% CBZ/ELF  PM 0.484 ± 0.008 0.715 ± 0.016 
C7 0.507 ± 0.011 0.638 ± 0.017 
C8 0.391± 0.006 0.537 ± .016 
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5.4.4. Surface area 
Surface area is considered as one of the important factors that affect the dissolution profiles of 
any drug. It was observed that increasing the surface area of any formulation will result in more 
contact with the dissolution medium and hence increase the in-vitro drug release. Moreover, the  
drug absorption will increase which enhance the drug bioavailability. Gemini VII, Micromeritics 
was used to measure the surface area of C1-C8. Table 5-4 shows the surface area and the 
calculated % porosity for C1-C8 formulations. The % porosity was calculated using the following 
equation: 
 
                     % 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 = (1 −
𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑖𝑠𝑡𝑦
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
) × 100                        (Equation 5-5) 
 
Formulations C2, C4, C6 and C8 exhibited higher surface area as well as higher % porosity 
compared to formulations C1, C3, C5 and C7. This is considered as a direct result of 
morphological change of C2, C4, C6 and C8 due to the injection of P-CO2 during the HME 
process. 
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Table 5-4: Surface area and % porosity of different drug loading CBZ /KlucelTM ELF with 
and without P-CO2 
Sample Name Surface Area (m2/gm) % Porosity 
C1 0.261 71 
C2 0.394 84 
C3 0.350 70 
C4 0.493 79 
C5 0.412 62 
C6 0.489 74 
C7 0.445 59 
C8 0.523 68 
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5.4.5. Scanning electron microscopy (SEM) 
SEM images were used to evaluate the morphological surface of the extrudates C1-C8. Figure 5-7 
presented the differences in the morphological characterization of formulations C1, C3, C5, C7 
(without P-CO2 injection) and formulations C2, C4, C6, C8 (with P-CO2 injection) by using 
longitudinal section (LS) of the extrudate samples. The images confirmed that all formulations 
processed with P-CO2 were porous that is one of the foam like structure characterization. While, 
the other extrudates formulated without P-CO2 were dense and no evidence of any pores in their 
extrudates structure was observed. 
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a 
b 
Figure 5-7: SEM image of LS of CBZ /Klucel
TM
 ELF extrudates a) without P-CO
2
 
injection, b) with P-CO
2
 injection. 
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5.4.6. CBZ Drug Content and Uniformity 
HPLC analysis was used to evaluate the drug content uniformity of all CBZ/KlucelTM ELF 
extrudates and physical mixtures with different drug loading that were used in this study. The 
results showed that, all physical mixture blends and extrudates were in an acceptable range of 
(93%-101%). With more focus on the formulations processed with P-CO2, the drug content 
results indicating more precision and uniformity of the drug in the polymer carrier (97%-101 
%.). These results may give more additional advantage of the carbon dioxide as a drug content 
uniformity enhancer. 
5.4.7. In-Vitro Drug Release 
As mentioned earlier, the in-vitro drug release profile is important for the prediction of the 
absorption and the bioavailability of any API. In many published reports, changing the 
morphology of the hot melt extrudates as well as increasing the surface area will enhance the 
release profile of the API. In this study, all the formulations processed with P-CO2 exerted an 
enhancement of CBZ release in water at 37oC compared to other formulations without P-CO2 
and the pure CBZ (Figure 5-8). Moreover, the CBZ release profile of the 50% drug load 
formulations processed with P-CO2 injection was less than 20%, 30% and 40% drug loading 
which have a complete drug release within 2 hours. While, the drug release profile of different 
drug loading formulations processed without P-CO2 injection results showed that 20% , 30%, 
40% and 50% having 90%, 86%, 80% and 73% CBZ drug release respectively. From these 
results, it can be concluded that 40% drug load is the saturation point of the CBZ/ Klucel TM. 
Because of reaching this point, 50% drug loading formulations C7 and C8 the CBZ dispersed as a 
mixture of amorphous and crystalline state. 
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Figure 5-8-a: Dissolution profiles of 20% CBZ/KlucelTM ELF extrudates with and without 
P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC). 
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Figure 5-8-b: Dissolution profiles of 30% CBZ/KlucelTM ELF extrudates with and 
without P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC). 
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Figure 5-8-c: Dissolution profiles of 40% CBZ/KlucelTM ELF extrudates with and 
without P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC). 
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Figure 5-8-d: Dissolution profiles of 50% CBZ/KlucelTM ELF extrudates with and 
without P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC). 
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f2 values were calculated to compare the formulations of the same drug loading with and without 
P-CO2 injection. The results showed that all f2 values were less than 50 (Table 5-5) indicating 
that dissolution profiles were not similar. Furthermore, 30% and 40% drug loading formulation 
exhibited significant dissimilarity with f2 values of 27.96 and 28.18 respectively. 
  Models independent approaches were used to understand and compare the drug dissolution 
profile of the same drug loading formulation with and without P-CO2 injection. The dissolution 
efficiency of all formulations processed with P-CO2 were increased compared with the same drug 
loading formulation processed without P-CO2 (Table 5-6). On the other hand, the mean 
dissolution time of all formulations processed with P-CO2
 were decreased compared with the 
same drug loading formulation processed without P-CO2 (Table 5-6). C4 and C6 formulation 
observed the maximum DE value of 70.577 % and 66.374% and the lowest MDT of 35.308 and 
37.987 minutes respectively. Based on f2, DE and MDT results it was confirmed that the 
injection of P-CO2 through HME process increased the CBZ/klucel
TM ELF solid dispersion drug 
load capacity up to 20% more than the regular HME process. 
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Table 5-5: Similarity factor of 20%, 30%, 40% and 50% CBZ /KlucelTM ELF formulations 
with and without P-CO2 
Formulation f2 Similarity Status 
C1 and C2 43.967 Dissimilar 
C3 and C4 27.960 Dissimilar 
C5 and C6 28.183 Dissimilar 
C7 and C8 43.744 Dissimilar 
 
Table 5-6: Dissolution efficiency and the mean dissolution time of 20%, 30%, 40% and 
50% CBZ /KlucelTM ELF formulations with and without P-CO2 
 
Without P-CO2 injection With P-CO2 injection 
DE* MDT** DE* MDT** 
20% CRZ 
/KlucelTM ELF 
50.276 53.291 61.800 45.837 
30% CRZ 
/KlucelTM ELF 
45.626 56.968 70.577 35.308 
40% CRZ 
/KlucelTM ELF 
40.941 59.296 66..374 37.987 
50% CRZ 
/KlucelTM ELF 
39.907 54.600 52.950 51.292 
 
DE*         Dissolution efficiency 
MDT**   Mean Dissolution Time 
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5.5. Conclusion 
Carbamazepine (CBZ) polymeric dispersions can be prepared using the novel technique of 
linking HME with P-CO2 injection. The resulted extrudates showed an increase in porosity and 
changed the macroscopic morphology to a foam-like structure due to expansion of the carbon 
dioxide at the extrusion die. HME processing assisted with P-CO2 increased the drug loading 
capability of CBZ in KlucelTM ELF polymeric matrix as well as optimized CBZ drug- release 
profiles. These processed properties of materials would provide numerous benefits during 
manufacturing of various solid dosage forms. 
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CHAPTER VI 
Dissolution Enhancement of the Psychoactive Natural Product- Piperine Using Hot Melt 
Extrusion Techniques 
6.1. Introduction 
Oral drug delivery is considered as the simplest and easiest route of the drug administration[61, 
62]. Oral bioavailability is mainly affected by drug solubility, permeability [63-66] and first pass 
metabolism [67]. In fact, most of the new APIs have low water solubility with low release 
profiles after oral administration. The biggest challenge in the pharmaceutical industry was to 
enhance the solubility, and the permeability of those drugs as key factors to improve their 
bioavailability. There are many techniques which have been used to improve the drug water 
solubility and release profile, and solid dispersions are considered to be the most successful 
techniques. There are two main solid dispersions manufacturing methods ; the melting methods 
such as hot melt extrusion; and solvent evaporation methods such as spray drying [15]. Hot melt 
extrusion (HME) is one of the most commonly used techniques to enhance the solubility and oral 
bioavailability of poorly soluble drugs as a beneficial technique for solid dispersion. It involves 
simple dispersion of poorly water soluble API in an inert carrier (polymer), where the drug could 
exist in amorphous or crystalline state. . There are many advantages of using HME due to the 
speed and the continuous manufacturing process. Moreover, since no solvent is required, it is 
considered to be a green method for enhancement of the solubility and oral bioavailability of 
poorly soluble drugs. Depending on the polymeric carrier; hot melt extrusion can be also used for 
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other purposes such as taste masking, controlling or modifying drug release and stabilizing the 
active pharmaceutical ingredient.  
Piperine (1-piperoylpiperidine) (Figure 6-1) is a crystalline pungent alkaloid isolated from black 
pepper (Piper nigrum), long pepper (Piper longum) and other pepper species (family: 
Piperaceae) [68-70]. Piperine is a poorly water soluble compound with a melting point at 135 oC. 
It has been extensively used in folk medicine in many Asian countries [69] and various studies 
have focused on investigating the pharmacological effects of piperine. Recently, it was reported 
as an anti-inflammatory, analgesic [71] [72], anti-depressant [73], cytoprotective, anti-leukemic 
and anti-oxidant agent [68, 74]. Furthermore, piperine significantly improves spatial memory and 
neurodegeneration in an Alzheimer’s disease animal model [75]. Furthermore, piperine was 
reported to be a bioavailability enhancer [76]. Pattanaik et al investigated that 20 mg oral 
piperine can enhance the bioavailability of phenytoin and carbamazepine by increasing their 
plasma dug concentration[77, 78]. Atal et al proved that piperine is a potent inhibitor of the drug 
metabolism [79]. Literatures reports show that piperine acts as a metabolic inhibitor which 
inhibits the drug metabolizing enzyme such as CYP3A4, CYP1B1, CYP1B2 and CYP2E1. [76] 
[80] [81]. This finding gave the interest to incorporate the piperine with the anti-cancer acetyl-
11-keto-ß-boswellic acid to increase its bioavailability and therapeutic efficacy [82]. 
Additionally, piperine modulate the permeability characteristics to increase the drug absorption 
through the cell membrane by increasing the vasodilation of the GIT membrane [70, 83]. Being a 
natural product, piperine had many advantages compared to other chemical entities such as low 
coast due to availability from plant material using easy and well known extraction and isolation 
methods [84]. Moreover, it is safe to use.     
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In the current study, the main goals were to enhance the solubility and the permeability of 
piperine in order to enhance its bioavailability and therapeutic efficacy. Three polymeric carriers 
Soluplus®, polyvinylpyrrolidone-co-vinylacetate 64 (Kollidon® VA 64) and Eudragit ® EPO were 
used via the hot melt extrusion process to accomplish these goals. 
6.2. Materials  
Piperine was purchased from Sigma-Aldrich (Milwaukee, WI 53233, USA), while Soluplus® and 
Kollidon® VA 64 were obtained from BASF- SE (Ludwigshafen, Germany), Eudragit ® EPO was 
received as a gift sample from Evonik Industries (Parsippany, NJ 07045, USA). All other 
chemicals and reagents used in the present study were of analytical grade and obtained from 
Fisher Scientific (Fair Lawn, NJ 07410 USA). 
 
 
 
Figure 6-1: Chemical structure of piperine. 
85 
 
6.3. Methods 
6.3.1. Thermogravimetric Analysis (TGA) 
TGA analysis were performed for piperine, Soluplus®, Kollidon® VA 64 and Eudragit ® EPO to 
evaluate their stability at the extrusion temperatures using a Perkin Elmer Pyris 1 TGA equipped 
with Pyris manager software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., 
Connecticut, USA). Approximately 10-15 mg of piperine, polymers as well as  physical mixtures 
were heated from 30°C to 300 °C at heating rate of 20°C/min. 
6.3.2. Differential Scanning Calorimetry (DSC) 
DSC studies were obtained using Perkin Elmer Pyris 1 DSC equipped with Pyris Manager 
Software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA). 
Approximately 2-4 mg of piperine, physical mixtures or extrudates were heated from 30°C to 
200°C at a heating rate of 10°C/min.  
6.3.3. Hot Melt Extrusion (HME) 
Piperine 10–40% w/w and Eudragit® EPO, Kollidon® VA 64 or Soluplus® (Table 6-1) were 
mixed using a V-shell blender (Patrtreson-Kelley Twin Shell Dry Blender) for 10 minutes. The 
resulting physical mixture blends were extruded using a twin-screw extruder (Process 11 Twin 
Screw Extruder, ThermoFisher Scientific) at the screw speed of 150 rpm at a temperature range 
of 100–130°C. All extrudates were milled and sieved through an ASTM #35 mesh to obtain a 
uniform particle size. 
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Table 6-1: Piperine formulation composition of HME  
 
 
 
 
 
 
Formulation 
Piperine (PIP) 
(%) 
Eudragit ® PE  
(%) 
Soluplus ® 
(%) 
Kollidon® VA 
(%) 
P1 10 90 - - 
P2 20 80 - - 
P3 40 60 - - 
P4 10 - 90 - 
P5 20 - 80 - 
P6 40 - 60 - 
P7 10 - - 90 
P8 20 - - 80 
P9 40 - - 60 
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6.3.4. Scanning Electron Microscopy (SEM) 
The morphology and physical state of the extrudates were evaluated using SEM analysis. 
Samples were mounted on adhesive carbon pads placed on aluminum and were sputter coated 
with gold using a Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a high 
vacuum evaporator. A JEOL JSM-5600 scanning electron microscope (SEM) operating at an 
accelerating voltage of 10kV was used for imaging.   
6.3.5. Fourier transforms infrared spectroscopy (FTIR) 
FTIR spectra of piperine, polymeric carriers, physical mixtures as well as extrudates were 
performed using Agilent Cary 630 FTIR spectrometer equipped with a DTGS detector. 2-4 mg 
sample was placed directly on ATR and the scanning range was 400 - 4000 cm−1 and the 
resolution was 1 cm−1. 
6.3.6. High Performance Liquid Chromatography (HPLC) 
 HPLC analyses were performed on all samples for piperine content using a Waters HPLC 
equipped with Empower software to analyze the data. HPLC consisted of a Waters e2695 
separation Module and Waters 2489 UV/Visible detector, (Waters Technologies Corporation, 34 
Maple St., Milford, MA 0157). The column used was Phenomenex Luna C18 (5µ, 250 mm × 4.6 
mm). The mobile phase consisted of a mixture of 0.1% ortho phosphoric acid and acetonitrile 
(45:55 v/v) with a flow rate of 1.2 mL/min and 20µL injection volume. The column temperature 
was 35oC (±2). The UV detector wavelength for piperine detection was set at λmax  262 nm [85]. 
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6.3.7. Solubility test 
The solubility was determined at pH 1.2, 5 (water), and 6.8 for formulations P4 - P9 as well as 
pure piperine. Sample equivalents to approximately 100 mg of piperine based on the drug load of 
each formulation were shaken in 20 mL scintillation vials containing 10 mL of tested pH 
solution. The samples were shaken at 80 rpm and at 25oC using Thermo Scientific Precision 
Reciprocal Shaking Bath. A sample volume of 1 mL was collected at time points 4, 10, 20 and 24 
h. The samples were filtered and analyzed by HPLC, and 1 mL of the same pH solution was 
added back to the scintillation vials to maintain the volume.  
6.3.8. In-vitro Drug Release 
A sample equivalent to 40 mg piperine of each extrudate as well as pure piperine were filled in 
gelatin capsules and the in-vitro drug release profiles were run using a USP type II dissolution 
apparatus. The used dissolution medium was 900 mL 0.1 N HCl maintained at 37 o C. A sample 
volume of 2 mL was taken at time points 10, 20, 30, 45, 60, 90, and 120 min. and was filtered 
and analyzed using HPLC; then2 mL of fresh dissolution medium was added back to the 
dissolution vessel at each time point to maintain the volume.  
6.3.9. Ex vivo permeability model (non-everted intestinal sac) 
The permeability studies were performed for the most promising formulation (P4) and pure 
piperine was used as the control. Non-everted intestinal sacs of male Sprague- Dawley rats, 
weighing approximately 200 -250 g, were provided from Charles river (Wilmington MA 01887, 
USA). Sacs of 4-5 cm in length were prepared. Each sac was filled with 0.5 mL of incubated 
Krebs-Ringer bicarbonate phosphate buffer, pH 7.4 with piperine 5mg/ml. Each non-everted sac 
was placed in 25mL beaker containing 5mL of Krebs-Ringer bicarbonate phosphate buffer, pH 
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7.4. A sample volume of 1 ml was taken from the solution outside the sac at time points of 0, 20, 
50, 80 and 120 minutes. The samples were filtered and analyzed for the content using HPLC. 
Fresh Krebs-Ringer buffer (1 mL) was added back to the beaker at each time point to maintain 
the volume. Cumulative dissolution profiles were calculated.  
6.4. Results and discussion: 
6.4.1. Pre-formulation Studies 
Under all utilized processing temperatures, TGA data showed no decrease in sample weight 
which indicate that all formulations in the study were stable under all applied extrusion 
temperatures.  
DSC data showed the endothermic crystalline melting peak at 135oC for pure piperine and all the 
physical mixture samples (Figure 6-2). Alternatively, all the extrudates showed absence of 
crystalline melting peaks in DSC data (Figure 6-3).  
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Figure 6-2: DSC thermogram of 10%, 20% and 40% of PIP/ Eudragit ® PEO, PIP/ 
Soluplus® and PIP/ Kollidon® VA 64 physical mixtures.  
 
 
Temperature (oC) 
H
ea
t 
F
lo
w
 E
n
d
o
 U
P
 (
m
W
) 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3: DSC thermogram of 10%, 20% and 40% of Piperine/ Eudragit ® PEO, 
Piperine/ Soluplus® and PIP/ Kollidon® VA 64 extrudates. 
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6.4.2. Hot Melt Extrusion (HME) 
 HME process was carried out using (Process 11 Twin Screw Extruder, fromThermo Fisher 
Scientific. The Thermo Fisher standard screw configuration was used in this study. The screw 
configuration consists of four conveying zones and three mixing zones (Figure 6-4). The hot melt 
extrusion processing conditions such as extrusion temperature, screw speed and the torque values 
are showen in (Table 6-2). The resulting extrudates were transparent, greenish yellow and brittle 
extrudates except for P3 (40% piperine0/ Eudragit
® EPO) which was opaque. This observation 
can be explained by the fact that 40% of drug load exceeded the Eudragit ® EPO carrier capacity 
allowing the extudate to mimic the appearance of the piperine only. All extrudates were milled 
using coffee grinder and sieved through an ASTM #35 mesh to obtain a uniform particle size. 
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Figure 6-4: Standard screw configuration of Process 11 Twin Screw 
Extruder, Thermo Fisher Scientific. 
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Table 6-2: Processing parameters for hot melt extrusion of PIP/ Eudragit ® PEO, PIP/ 
Soluplus® and PIP/ Kollidon® VA formulations 
 
Formulation 
Processing 
Temperature  
(oC) 
Screw Speed 
(rpm) 
Torque 
(Nm) 
Extrudate 
Image 
P1 110 150 6-7 
 
 
P2 110 150 4-5 
 
 
P3 110 150 3 
 
 
P4 120 150 7-8 
 
 
P5 120 150 4-5 
 
 
P6 120 150 3-4 
 
 
P7 130 150 7-8 
 
 
P8 130 150 3-4 
 
 
P9 130 150 3-4 
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6.4.3. Scanning electron microscopy (SEM) 
SEM images showed absence of crystals in 10% w/w piperine/Soluplus® indicating that piperine 
was dispersed in the Soluplus® polymer carrier as an amorphous form. This may help to enhance 
the solubility and the bioavailability of this formulation. However, crystals were evident in the 
other piperine/ Soluplus® formulations with different ratios (Figure 6-5). In addition, SEM 
images demonstrated crystals in Kollidon® VA 64 and Eudragit ® EPO formulation (Figure 6-6). 
These results are not consistent with the DSC results that showed absence of the piperine 
crystalline peak in the resulting extrudates. This observation be explained the fact that all  
polymers used in this study i.e., Eudragit® EPO, Kollidon® VA 64, and Soluplus® had a Tg 
temperature of 45 oC, 101 oC and 70 oC respectively which are lower than the piperine melting 
point. Due to this; the polymers used will soften before the melting temperature of piperine 
allowing the piperine to solubilize in the polymer matrix and prevent the melting peak 
appearance. 
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 Figure 6-5: SEM of extrudates: a) 10% w/w piperine/Soluplus
®
, b) 20% 
w/w piperine/Soluplus
®
, c) 40% w/w piperine/Soluplus
®
.    
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Figure 6-6: SEM of extrudates: a) 20% piperine/Eudragit
 ® 
EPO, b) 
20% piperine/Kollidon
 ® 
VA64.  
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6.4.4. Fourier transforms infrared spectroscopy (FTIR) 
FTIR analysis was performed to evaluate any chemical or physical interaction between piperine 
and the different polymeric carriers. Figure 6-7 shows the FTIR spectra of Soluplus and their 
formulations, the physical mixture displays a sharp peak at 1623 cm-1, and this peak shifts to 
approximately 1629 cm-1 for all Soluplus formulations confirmed the presence of hydrogen 
bonding between piperine and Soluplus®. While, there were no shift observed in Eudragit® EPO 
(Figure 6-8), and Kollidon® VA 64 formulations (Figure 6-9). The formation of hydrogen 
bonding will increase the stability of the Soluplus solid dispersion formulations and prevent 
recrystallization of piperine [15, 86, 87]. 
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Figure 6-7: FTIR spectra of Soluplus
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, piperine, 10% piperine /Soluplus
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, 
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® 
extrudates. 
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Figure 6-8: FTIR spectra of Eudragit
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Figure 6-9: FTIR spectra of Kollidon
 ®  
VA 64, piperine, 20% piperine / Kollidon
 ®  
VA 64 physical mixture and extrudates. 
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6.4.5. Solubility Evaluation 
The shake- flask method was used to determine the piperine solubility at pH value at equilibrium 
state [88].Solubility study was performed for formulations P4, P5, P6, P7, P8 and P9 using three 
different solvents pH (1.2, 5 [(water)], and 6.8) to evaluate whether piperine solubility is pH 
dependent or not. The pH did not have any effect on the solubility of piperine as there were slight 
changes in the solubility values at pH 1.2 and 6.8 (Table 4-3). Furthermore, in formulations P4 
P5, P6, P7, P8 and P9 water solubility of piperine increased more than 160, 45, 25, 20, 5 and 3 
folds respectively compared to pure piperine solubility in water (Table 6-3). This significant 
enhancement in the water solubility of piperine in P4 was due to the dispersion of piperine in its 
amorphous state. Amorphous solid dispersion play a significant role in increasing the solubility 
and the dissolution rate of poorly water soluble APIs [89-92]. In general, amorphous API is more 
soluble than crystalline ones because of its higher effective surface area than the crystalline form 
[93-95]. However, the main problem associated with amorphous API is its instability, which can 
lead to recrystallization during storage as well as during dissolution [96]. In contrast, amorphous 
solid dispersions are stable as the polymeric carrier prevent the API recrystallization [97]. 
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Table 6-3: Solubility of piperine and piperine formulation in water, pH 1.2 and 6.8  
 
Formulation 
Solubility in Water 
(mg/L) 
Solubility in pH 1.2 
(mg/L) 
Solubility in pH 
6.8 
(mg/L) 
Piperine  1 0.9 0.9 
P4 163 117 117 
P5 47 39 45 
P6 27 21 27 
P7 20 18 17 
P8 6 6 6 
P9 3 3 3 
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6.4.6. In-vitro Release Profiles 
Dissolution studies demonstrated improvement in piperine drug release of 10% and 20% w/w 
piperine/Soluplus® extrudates up to 95% and 74%, respectively (Figure 6-10). However, no 
effect on piperine drug release profiles for other formulations was noted due to remaining of 
piperine in the crystalline state. These results confirmed that the dispersion of piperine in 
amorphous state plays a big role in enhancing the solubility [98] and drug release. Additionally, 
it can be concluded that the maximum drug loading capacity of piperine in Soluplus to form 
stabilized amorphous solid dispersion is approximately 10%. Soluplus® (Polyvinyl caprolactam-
polyvinyl acetate-polyethylene glycol graft copolymer) is a relatively new polymer designed 
mainly for use in solid dispersion preparation ApIs [99]. It acts as a polymeric stabilizer and 
solubilizing agent to improve the solubility and bioavailability of poor water soluble APIs [100-
102]. It is a good polymeric carrier candidate to prepare amorphous solid dispersions of many 
poor water soluble APIs such as clotrimazole, carbamazepine, griseofulvine, and itraconazole by 
improving their dissolution profiles as well as their intestinal absorption and bioavailability 
[100]. In the recent study, Soluplus® was successfully used to prepare 10% piperine amorphous 
solid dispersion with a significant increase in the piperine release profile.   
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Figure 6-10: In-vitro release profiles of 10% w/w piperine/Soluplus®, 20% w/w 
piperine/Soluplus®, 40% w/w piperine/Soluplus®, 20% piperine/Eudragit ® EPO, 
20% piperine/Kollidon ® VA64 and pure piperine. 
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6.4.7. Ex vivo permeability model (non-everted intestinal sac) 
There are many in vivo, ex-vivo and in vitro assays used to evaluate the intestinal drug 
permeability [103, 104]. These assays include  perfusion, diffusion chambers, gut sac, cultured 
cell and artificial membrain [105]. The results of a research investigation showed that there was a 
good correlation between rat and human oral absorption. There are two types of  rat intestinal sac 
models which are used to evaluate the drug permeability, everted and non-everted sacs. Some 
studies have been done to compare the permeability values of some APIs through both everted 
and non-everted sacs and no significant difference was observed in the permeability results. In 
this study, non everted rat intestinal sac model have been used to give an idea about the piperine 
absorption in humans. The permeability study results (Figure 6-11) demonstrated the 
enhancement in piperine absorption of 10% w/w piperine/Soluplus® up to 158.9 μg/5mL 
compared to 1.4 μg/5mL in the case of pure piperine within 20 min. as a direct result of the 
solubility improvement. 
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Figure 6-11: Piperine absorption characteristics using jejunum non-everted sac under 
normal physiological conditions (Krebs Ringer bicarbonate phosphate buffer, pH 7.4). 
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6.5. Conclusion 
HME was successfully used to enhance the solubility of the psychoactive natural product 
piperine. The drug release profiles of 10% and 20% w/w piperine/Soluplus® hot melt extrudates 
were significantly enhanced due to piperine in its amorphous state. In addition, the formation of 
hydrogen bond between piperine and Soluplus® may inhibit drug recrystallization and assist in 
the maintenance of the drug in its amorphous form thereby enabling good formulation stability. 
Furthermore, a significant improvement in piperine permeability has been confirmed using a 
non-everted rat intestinal sac. These results demonstrate that increase the absorption and 
bioavailability of piperine are possibilities. 
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